Abstract: Methods can be used for producing three-dimensional objects by powder bed fusion, using inks containing superparamagnetic particles and solvents. Sintering is performed by a magnetic field having a frequency of 50 kHz to 5 GHz.

Abstract: A silane composition contains at least one iminosilane and at least one antioxidant. The at least one antioxidant is a sterically hindered phenol. A process can be used for the production of the silane composition.

Abstract: A modified colloidal silica is produced by mixing an effective amount of an alkyl silicate to form a colloidal silica, followed by treating the colloidal silica with an effective amount of a polyethersilane to form a modified colloidal silica.

Abstract: The present invention relates to a formulation comprising: i) at least one hydrolysate of at least one compound of formula (I) RSi(OX)3 (I) where X, the same or different, is H, C1-C4 alkyl or acyl, R=OX, OH, C1-C4 alkyl or alkoxy silyl-substituted ethylene radical, ii) at least one hydrolysate of at least one polyisocyanurate bearing alkoxy silyl alkyl units, iii) at least one polymer bearing hydroxyl groups, and iv) a solvent mixture containing water comprising at least one alcohol with 1 to 4 carbon atoms, wherein the pH value of the formulation lies in a range from 1.8-4.7, preferably from 3-4.5, and the content of the polymer bearing hydroxyl groups ranges from 13 wt. % to 33 wt. % related to the solids content in the formulation. The invention further relates to a method for the production of said formulation, the use thereof in the production of laminate structures and corresponding laminate structures having at least two layers comprising the formulation.

Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

Abstract: The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of the 5-HT2C receptor, and processes for preparing such compounds and compositions.

Abstract: The present invention relates to compound of formula (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

Abstract: A modified colloidal silica is produced by mixing an effective amount of an alkyl silicate to form a colloidal silica, followed by treating the colloidal silica with an effective amount of a polyethersilane to form a modified colloidal silica.

Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

Abstract: The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl-bound N-amide moiety derived from an ?-amino acid of formula I where the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, and to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT2C receptor.

Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

Abstract: The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

Abstract: Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.

Abstract: The invention relates to a composition for use in a Monosil process for the crosslinking of thermoplastic polyolefins which comprises (i) from 5 to 60% by weight content of 2-ethyl hexanoic acid [H3C(CH2)3CH(C2H5)COOH], (ii) content of at least one monounsaturated organofunctional alkoxysilane of the general formula I A-SiR2x(OR1)3-x??(I), where R1 is mutually independently a linear or branched hydrocarbon moiety having from 1 to 4 C atoms, R2 is methyl and x is 0 or 1 and A is a monovalent olefin group of the formula (R3)2C?C(R3)-Mk-, where k is 0 or 1, in which groups R3 are identical or different and R3 is a hydrogen atom or a methyl group and the group M is a group from the following list: —CH2—, —(CH2)2—, —(CH2)3— and —C(O)O—(CH2)3—, (iii) content of at least one free-radical generator and (iv) optionally content of at least one other component, where the entirety of all components (i) to (iv) gives 100% by weight.

Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.

Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.

Abstract: The present invention relates to compound of formula (I) as tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, useful for modulating the 5-HT2C receptor and preventing and/or treating conditions and disorders that respond to the modulation of the 5-HT2C receptor. The present invention also relates to methods for producing compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for preventing or treating conditions and disorders that respond to the modulation of the 5-HT2C receptor by administering compounds of formula (1) or pharmaceutical compositions thereof.

Abstract: The present invention relates to novel carboxamide compounds and their use as a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity and to a method for the therapeutic and/or prophylactic treatment by administering an effective amount of at least one of these carboxamide compounds. The carboxamide compounds are compounds of the general formula I in which W—R2 is selected from and R1, R2, R3a, R3b, Y1, Y2, Y3, Y4, X, Q, m, k, Rw and Rw* have the meanings mentioned in the claims, the tautomers thereof and the pharmaceutically suitable salts thereof.